An observational study in Non Small Cell Lung Cancer, sponsored by University Hospital, Angers. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by University Hospital, Angers · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 873 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 168 open to participants now, 327 under way, 106 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.
Among the 873 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 77th largest by planned enrollment of the 104 observational ones that give a count, is one of 59 that started in 2025, is one of 104 observational ones, reaches primary completion later than 257 of the 326 other live ones, and was the 728th registered.
7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →168 of the 873 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:
Centre Georges Francois Leclerc · Sites in France
Ages 18+
Centre Leon Berard · Sites in France
Ages 18+
Daiichi Sankyo · Sites in France, United States, Argentina and 10 more countries
Ages 18+
Hoffmann-La Roche · Sites in France, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
873 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 205 · Phase 2 338 · Phase 3 252 · Phase 4 9
First in 1994; this study’s year is marked. 59 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 160 across 1,148 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 190 across the 760 interventional studies, 151 across the 104 observational. Of the 512 that completed or were terminated, 257 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
611 of 873 have an industry lead sponsor. The 10 most frequent:
University Hospital, Angers is the lead sponsor of 478 studies on the registry; 120 are open to participants now.
University Hospital, Angers has 3 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
68 of the studies in Carcinoma, Non-Small-Cell Lung with a site in France that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT03774732Phase 3UNICANCERPD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer | 2026-12-22 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
Add all 68 to your calendar (.ics) → With an account.
Among the 873 studies in Carcinoma, Non-Small-Cell Lung with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Solid cancers and their therapeutic management remain a major public health problem due to their increasing prevalence and associated mortality. Among solid cancers, lung cancer ranks 4th among incident cancers. The prognosis remains poor, 33,117 deaths were recorded in France in 2018. Two histological forms of bronchopulmonary cancer are distinguished: non-small cell lung cancers (NSCLC), which represent 85% of bronchopulmonary cancer, and small cell lung cancers. The most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
The emergence of new so-called targeted therapies has considerably modified the management and prognosis of oncology patients and in particular of patients with NSCLC. These new molecules were developed following the molecular characterization of tumors on the one hand and on the other hand the characterization of the role of immunity in anti-tumor defense, particularly the Programmed Death receptor pathway 1 (PD-1). Blocking this pathway restores the anti-tumor potential of these lymphocytes. Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the Programmed Death Ligand-1 (PDL1) and Programmed Death Ligand-2 (PDL2), expressed by tumor cells but also by cells in the microenvironment. tumor and by antigen-presenting cells. Pembrolizumab thus potentiates T cell responses, including anti-tumor responses, by blocking the binding of PD-1 with PDL1 and PDL2.
Pembrolizumab currently has marketing authorization (MA) for the treatment of NSCLC. Despite therapeutic progress due, among other things, to the emergence of anti-PD-1 antibodies including pembrolizumab, the prognosis of NSCLC remains poor and the use of pembrolizumab is sometimes limited by the occurrence of adverse effects.
The pharmacokinetics of pembrolizumab was studied pre-marketing in patients with melanoma, NSCLC or metastatic or unresectable carcinomas. However, there are no data relating to the pharmacokinetic (PK) / clinical response (pharmacodynamic / PD) relationship of pembrolizumab, in real life. No prospective pharmacological study has in fact been published to date, especially in patients treated as part of the management of NSCLC. The absence of such studies - in real life - constitutes a pitfall given the existence of a possible association between PK data and the clinical response and/or toxicity of pembrolizumab.
This is a population pharmacokinetic study aimed at establishing the PK-PD relationship in patients with NSCLC treated with pembrolizumab (non-comparative descriptive study).
Taking into account the half-life (26 days) and the time necessary to obtain the equilibrium state (16 weeks), the choice was made to take residual and peak samples during administrations. This sampling strategy will allow the construction and validation of the PK model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.
Pembrolizumab efficiency Month 2
Pembrolizumab effectiveness according to RECIST's radiological criteria
Time frame: month 2
Pembrolizumab efficiency Month 4
Pembrolizumab effectiveness according to RECIST's radiological criteria
Time frame: month 4
Pembrolizumab efficiency Month 12
Pembrolizumab effectiveness according to RECIST's radiological criteria
Time frame: month 12
Pembrolizumab toxicity Month 18
All adverse/toxic reactions collected by Regional Safety center until 18 months
Time frame: month 18
Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.
Of 356 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 42 months is below that.
Counting every sponsor, half of 498 studies reached it within 55 months; a quarter within 35 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →